Abiopharma

New Form S-1/A - BIOVIE INC. Filed: 2025-08-04 AccNo: 0001520138-25-000235 Size: 8 MB

New Form 8-K - Praxis Precision Medicines, Inc. Filed: 2025-08-04 AccNo: 0001689548-25-000094 Size: 3 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - MetaVia Inc. Filed: 2025-08-04 AccNo: 0001558370-25-010031 Size: 233 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

The Gross Law Firm Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - CAPR

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

New Form DEFA14A - Genprex, Inc. Filed: 2025-08-04 AccNo: 0001437749-25-024488 Size: 642 KB

New Form 8-K - Genprex, Inc. Filed: 2025-08-04 AccNo: 0001437749-25-024487 Size: 830 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Equillium, Inc. Filed: 2025-08-04 AccNo: 0001193125-25-172207 Size: 530 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 424B5 - HeartSciences Inc. Filed: 2025-08-04 AccNo: 0001213900-25-070893 Size: 20 KB

New Form 10-Q - Praxis Precision Medicines, Inc. Filed: 2025-08-04 AccNo: 0001689548-25-000092 Size: 5 MB

Star Equity Holdings to Release Second Quarter 2025 Financial Results on August 13

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results